George Kaiser Family Foundation Acquires New Stake in Eli Lilly and Company (NYSE:LLY)

George Kaiser Family Foundation acquired a new stake in Eli Lilly and Company (NYSE:LLY) during the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 309 shares of the company’s stock, valued at approximately $255,000.

Other institutional investors have also added to or reduced their stakes in the company. WestEnd Advisors LLC lifted its position in Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after acquiring an additional 21 shares in the last quarter. Citizens National Bank Trust Department lifted its position in Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after acquiring an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company in the 1st quarter valued at $40,000. Mascagni Wealth Management Inc. acquired a new stake in Eli Lilly and Company in the 4th quarter valued at $43,000. Finally, O Brien Wealth Partners LLC increased its stake in Eli Lilly and Company by 25.5% in the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock valued at $49,000 after buying an additional 12 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $701.51 on Friday. The company has a 50 day moving average of $764.55 and a 200-day moving average of $794.63. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $972.53. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company has a market cap of $663.95 billion, a PE ratio of 45.85, a price-to-earnings-growth ratio of 0.98 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the firm posted $3.92 EPS. The firm’s quarterly revenue was up 37.6% on a year-over-year basis. As a group, equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.9%. Eli Lilly and Company’s dividend payout ratio is presently 39.22%.

Insiders Place Their Bets

In other news, Director J Erik Fyrwald acquired 1,565 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the acquisition, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. The trade was a 2.14% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Gabrielle Sulzberger acquired 117 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the acquisition, the director owned 2,703 shares in the company, valued at $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 4,514 shares of company stock worth $2,894,841 over the last 90 days. Insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on LLY. Hsbc Global Res lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research note on Monday, April 28th. Wells Fargo & Company reiterated an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Wall Street Zen upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. Leerink Partnrs lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 7th. Finally, Guggenheim lowered their price target on shares of Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating on the stock in a research note on Wednesday. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $964.88.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.